# Biotechnology
Latest news and articles about Biotechnology
Total: 22 articles found
A Bitter Pill: Trump’s 100% Drug Tariffs and the Future of Chinese Biotech
President Trump has signed an executive order under Section 232 to impose 100% tariffs on imported patent drugs and APIs, aimed at forcing price concessions and manufacturing onshoring. While Chinese biotech firms face new challenges, many are already pivoting toward U.S.-based production to mitigate these trade risks.
Precision Oncology Gains Ground in China: AmoyDx Secures Regulatory Nod for c-Met Lung Cancer Diagnostic
Amoy Diagnostics has received NMPA approval for its c-Met gene amplification kit, a companion diagnostic for the lung cancer drug Savolitinib. This development marks a vital step in China's push for localized precision oncology and sophisticated personalized medicine tools.
Haier Refutes ‘Vampire’ Therapy Claims as Fringe Wellness Hits Corporate China
Haier Group has issued a formal denial regarding any involvement in controversial 'blood-replacement' therapies or partnerships with entrepreneur Yu Wenhong. The conglomerate is pursuing legal action to protect its healthcare brand, Yingkang Life, from reputational damage caused by fringe medical claims.
China’s Gene-Edited Swine: A New Frontier in Combating Human Metabolic Disease
Chinese scientists have successfully cloned the world's first gene-edited pigs targeting the LXRα receptor, a key regulator of cholesterol and inflammation. This breakthrough provides a sophisticated new animal model for studying how metabolic disorders trigger cardiovascular disease in humans.
The Algorithmic Apothecary: Insilico Medicine Nets High-Stakes AI Drug Pact with Eli Lilly
Insilico Medicine has entered a strategic collaboration with Eli Lilly to utilize generative AI for drug discovery, marking a significant milestone in the integration of AI into Big Pharma's R&D pipelines. The partnership validates Insilico's Pharma.AI platform and signals a broader industry shift toward algorithmic molecular design.
China’s ‘Anti-Cancer Nuclear Bomb’ Breakthrough: Breaking the Global Monopoly on Medical Isotopes
Chinese scientists have achieved Curie-level mass production of medical alpha isotopes using the China Spallation Neutron Source, breaking a long-standing reliance on expensive imports. This breakthrough significantly lowers the cost of precision cancer therapies and establishes a robust domestic supply chain for next-generation radiopharmaceuticals.
Fragile Resilience: China’s Markets Rebound as Geopolitical Shadows Loom
The Shanghai Composite rebounded to close above 3,913, driven by biotech and lithium battery sectors, despite thinning trading volumes and rising geopolitical risks. Market sentiment remains tethered to developments in the Middle East and shifting U.S.-China diplomatic signals, favoring a structural rather than a broad-based recovery.
China’s 'In Vivo' Breakthrough: A New Frontier in Autoimmune Disease Treatment
Chinese researchers from Shandong University have developed a breakthrough method for treating autoimmune hepatitis through in-body cell reprogramming. This 'in vivo' approach offers a more efficient alternative to traditional CAR-T therapies and signals a major shift in how autoimmune diseases may be treated globally.
Weiguang Bio Advances Patient-Centric Care with Subcutaneous Immunoglobulin Trial Approval
Weiguang Biological has received NMPA approval to begin clinical trials for a subcutaneous human immunoglobulin injection. The therapy targets primary immunodeficiency diseases and represents a shift toward home-based, patient-friendly administration in the Chinese plasma market.
China’s Fountain of Youth: The Dangerous Rise of the Underground Stem Cell Market
China is witnessing a surge in illegal stem cell infusions marketed as high-priced anti-aging treatments, often involving collusion between private firms and public hospital doctors. Despite costs reaching $55,000 per shot, there is no scientific evidence or regulatory approval for these therapies, posing significant health and financial risks to consumers.